Plain-English translation of NCT05601726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called for patients with two serious blood cancers — acute myeloid leukemia and myelodysplastic syndromes — who have already tried other treatments without success or who cannot receive standard therapies. The study will gradually increase the dose in different groups of patients to find the safest and most effective dose, and then test that dose repeatedly over several treatment cycles.
Patients with relapsed or treatment-resistant blood cancers have very limited options, and many cannot receive standard intensive chemotherapy or newer targeted drugs. This trial exists to see whether this medication could offer a new hope for these patients.
You likely qualify if…
You likely don't qualify if…
The trial happens in two phases. In the first phase, you will receive a single dose of the medication as a 4-hour intravenous infusion, with different patients receiving different doses to find the safest level. If that phase goes well, the second phase involves receiving multiple doses on a set schedule over three 28-day treatment cycles. Throughout the study, you will have frequent blood tests and monitoring visits to check how the medication is working and how your body is tolerating it.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France